Follow on Google News News By Tag * Pharmaceutical * Biopharmaceutical * Medical * Health * Medicine * Healthcare * Biotechnology * Pharmco * Drugs * Oncology * More Tags... Industry News News By Location Country(s) Industry News
Follow on Google News | In 2010, Is There Any Difference Between the Biopharmaceutical and Pharmaceutical Industry?Latest report by Kalorama Information examines the current state of the biopharmaceutical and pharmaceutical industry, and what the market will look like in five years.
By: Kalorama Information Among the top companies in biopharmaceuticals are, not surprisingly, the same names that have dominated pharmaceuticals for years – Pfizer, Merck and Novartis. These companies have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts. Specialist companies such as Amgen and Genzyme, now competing with a growing number of companies. The result of all interest in biological solutions to major diseases? In creased activity in the research and development departments of major pharmaceutical companies in recent years, activity that we believe will have near-term market impact. “If you ask a traditional pharmco these days what they are, they are going to say a pharmaceutical and biopharmaceutical company,” said Mellisa Elder, analyst for Kalorama Information. “The late-stage pipeline of Merck, Pfizer and Novartis features a good number of mabs and other biopharmaceutical candidates.” Fifty companies produce 95% of the revenue in the pharmaceutical market. Collectively, these companies have 550 programs in late stage development. We include where one candidate is submitted for multiple indications. Drugs in the oncology segment are expected to make a significant impact to current markets, increasing competition and providing advanced alternatives to current therapies. Many of these are monoclonal antibodies or other biologic therapies. Cancer drugs in development could possibly make up nearly a third of the market impact of all of these new treatments This is followed by development projects in the areas of cardiovascular and blood; neurotherapeutics; The global pharmaceutical market is now worth approximately $600 billion (at the manufacturer’ The World Pharmaceutical and Biopharmaceutical Market 2010-2015 (Pipeline Analysis of the Top 50 Companies) can be obtained at http://www.kaloramainformation.com/ Please direct all media inquiries to: Andrea Hiller press@kaloramainformation.com http://www.kaloramainformation.com/ # # # About Kalorama Information Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter: www.twitter.com/ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|